The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Primacine 250 mg/5 ml Granules for Oral Suspension

250 mg/5ml Granules for oral suspension

Pinewood Laboratories Ltd,PA0281/026/008

Main Information

Trade NamePrimacine 250 mg/5 ml Granules for Oral Suspension
Active SubstancesERYTHROMYCIN ETHYLSUCCINATE
Strength250 mg/5ml
Dosage FormGranules for oral suspension
Licence HolderPinewood Laboratories Ltd,
Licence NumberPA0281/026/008

Group Information

ATC CodeJ01FA Macrolides
J01FA01 erythromycin

Status

Authorised/WithdrawnAuthorised
Licence Issued13/11/1998
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back